Piscataway, NJ, March 28, 2024 – Camber Pharmaceuticals is pleased to announce the addition of Mesalamine Delayed- Release Tablets, USP to its product line.
Mesalamine Delayed- Release Tablets are indicated for the induction and maintenance of remission in adult patients with mildly to moderately active ulcerative colitis.
Mesalamine Delayed- Release 1.2 g Tablets are available in a 120 count bottle.
To learn more about Mesalamine Delayed- Release Tablet, USP, please visit https://www.camberpharma.com/mesalamine-dr
